anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A composition is provided to suppress NO generation without cytotoxicity, to suppress airway resistance, inflammatory materials, lung tissue protein STAT4 and STAT6, and T cell activation, and to increase anti-inflammatory materials. CONSTITUTION: A composition for preventing and treating bronchial asthma contains a mixture extract of Rehmannia glutinosa, Pinellia ternate, Citrus reticulate, Glycyrrhiza glabra, Platycodon grandiflorum, and Schizandra chinensis as an active ingredient. The mixture extract is prepared using 70% methanol. The daily dose of the mixture extract is 0.0001-10 mg/kg. A health functional food for preventing and treating bronchial asthma contains the mixture extract as an active ingredient. The health functional food further contains a sitologically acceptable food additive. [Reference numerals] (AA) Extraction with water, OMC 0.1mg/kg + OVA; (BB) Extraction with water, OMC 1mg/kg + OVA; (CC) Extraction with methanol, OMC 0.1mg/kg + OVA; (DD) Extraction with methanol, OMC 1mg/kg + OVA
A device includes a bottom housing that includes a printed circuit board, a processor formed on the printed circuit board, a probe tip coupled to the processor, and a first wall. The first wall includes a front side surface, a backside surface, and an opening extending from the front side surface to the backside surface. The printed circuit board is coupled to the front side surface of the first wall. The printed circuit board includes a plurality of electrical contacts located on the back surface and coupled to the processor. The electrical contacts on the backside surface of the printed circuit board are visible through the opening formed in the first wall of the bottom housing. The electrical contacts are sealed from fluid penetration and can connect to the electrical contacts of a battery connected to the device.
Side effects of Norgesic Forte Tablets are those seen with aspirin and caffeine or those usually associated with mild anticholinergic agents. These may include tachycardia, palpitation, urinary hesitancy or retention, dry mouth, blurred vision, dilation of the pupil, increased intraocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, and rarely, urticaria and other dermatoses. Infrequently, an elderly patient may experience some degree of confusion. Mild central excitation and occasional hallucinations may be observed. These mild side effects can usually be eliminated by reduction in dosage. One case of aplastic anemia associated with the use of Orphenadrine Citrate, Aspirin, and Caffeine Tablets has been reported. No causal relationship has been established. Rare G.I. hemorrhage due to aspirin content may be associated with the administration of Norgesic Forte Tablets. Some patients may experience transient episodes of lightheadedness, dizziness or syncope.
A method, system and computer program product for evaluating or determining a user's insulin sensitivity (SI). An initial step or module may include acquiring SMBG readings from a predetermined period. Another step or module may include computing an estimate of insulin sensitivity (SI) from the SMBG readings. Another step or module may include using the estimate of SI to compute individualized carbohydrate ratio. Additionally, another step or module may include using the estimate of SI to compute individualized correction factor. The computation of the two components of an insulin dose calculator, carbohydrate ratio and correction factor, uses this estimate, which allows the tailoring of carbohydrate ratio and correction factor to the present state of the person.
Recent evidence indicates that there is a marked increase in the mobilization of lead from maternal bone stores into circulation during pregnancy and lactation. Furthermore, data from our group and others indicate that this phenomenon carries a significant risk of fetal toxicity in the form of growth (decreased birth weight, head circumference, birth length) and subsequent cognitive development. These findings pose a major public health problem, even among societies with declining lead exposure, given the persistence of pockets of high lead exposure (including some communities living in proximity to hazardous waste) as well as the long residence time of lead in bone (years to decades). One possible strategy for suppressing the mobilization of maternal bone lead stores during pregnancy is nutritional intervention. We are conducting a randomized, double-blinded, placebo-controlled trial of dietary supplements containing 1,200 milligrams of calcium as a means of suppressing bone resorption and the resulting mobilization of lead from bone into plasma during pregnancy, and into breast milk during the postpartum period. We are taking maternal measurements of pre-pregnancy and postpartum bone lead using our K-x-ray fluorescence technology; bone resorption (by assaying N-telopeptide of type I collagen in urine \[urinary NTX\]), whole blood lead, and plasma lead (using special collection techniques and measured by IDTIMS) during pre-pregnancy, the first, second, third trimesters and at one and four months postpartum; and breast milk lead levels at one and four months postpartum.

We are measuring maternal plasma and breast milk lead levels as these are the most direct sources of fetal and infant lead exposures, and recent research suggests that maternal venous blood lead levels do not adequately reflect either of these parameters. We are testing the hypothesis that supplements will significantly decrease urinary NTX, plasma lead, and breast milk lead levels. We are also exploring the relationship of plasma lead levels to birth anthropometry measures. This research, if successful, may provide a means of preventing secondary toxicity from accumulated lead burdens among women of reproductive age.
Patients receive sunitinib malate PO daily for 4 weeks. Patients undergo neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline and on days 14 and 28.
Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation includes 6 levels, Q3W IV. Dose extension will be carried out at the selected level.
The present invention relates to a traditional Chinese medicine product used as both a medicine and food for preventing and treating weak waist and leg, and a making method thereof. The traditional Chinese medicine product is prepared from traditional Chinese medicines officially used as both medicine and food: common yam rhizome, common floweringquince fruit, gordon euryale seed, coix seed, palmleaf raspberry fruit, etc. The present invention has the advantages of low production cost, no environmental pollution, no difference in people and age, good mouth feel, small dosage, good effect and easy acceptance by patients. The combined medicinal materials of the traditional Chinese medicine and the medicine properties have the functions of protection and coordination to the heart, the lungs, the spleen and the kidneys, and embody the whole concept and advantages of the traditional Chinese medicine sufficiently so as to complete medicine effects and functions to treat both manifestation cause and root cause of a disease and realize a very high bourn that the whole medicine properties of the traditional Chinese medicines tend to be mild and raise medicine effect mutually. Furthermore, as all the medicinal materials are all official medicines and food, the effect is affirmative without toxic or side effect. The present invention is suitable for any crowd with wide service range; the used variety and the functions of the medicines are simple and clear; formulas are flexible and various and adapt to various states of illness with suitable medication selection; the particular content and the application range of the determination of treatment based on different symptoms and signs of the traditional Chinese medicine and pharmacy are widened.
A system and method of providing information concerning pathological findings evidenced by radiographical reports. A medical care provider may request a radiographical image, in particular, an MRI image of a region of the body. The region of the patient's body is scanned and the images are read and interpreted to determine if there is a positive finding of a pathology. If a pathology is detected, the generated scanned images are reviewed for a radiographical image that best depicts the detected pathology and the image is selected for further annotation. The image is then annotated to highlight and more fully describe and delineate the pathology thus alerting the medical care provider of the pathology's existence. In addition, the report may be further delineated with an identifying mark informing the referring physician of a positive finding of a pathology.
1320309 Compositions in sheet form V P VARIOPHARM GmbH 19 April 1971 [18 March 1970] 24495/71 Heading A5B [Also in Division B2] Pharmaceutical and cosmetic compositions in the form of flexible sheets and films are made by forming an oil-in-water emulsion containing the active material and a water soluble or swellable film former and reducing the water-content of a thin layer thereof to from I to 15%. The oil phase of the emulsion is or comprises an oily or oleaginous substance such as an animal, vegetable or mineral oil. A conventional emulsifier is present as well as the film-former which may be a water-dispersable or swellable cellulose derivative, or an alginate. In an example, a piece of mull is incorporated into the sheet and reference is made to applying the sheet material to a backing such as a bandage or adhesive tape. Numerous active materials which may be incorporated are specified as well as such ingredients as TiO 2 and ZnO which increase covering power of ointments. (From GB1320309 A) [FR2083366A1]
NEW MATERIAL:A compound shown by the formula (n is 20-25). EXAMPLE:1-beta-D-(22-Hydroxydocosanoyl)glucose. USE:A surface active agent being readily synthesized chemically and having high safety. PREPARATION:Bark of Virola sebifera as a raw material is extracted with an organic solvent. The prepared extracted essence is treated with an acid and separated into an acid-soluble part and an acid-insoluble part. The acid- insoluble part is dissolved in an organic solvent, the dissolved part is subjected to adsorption chromatography and optionally ordinary purification treatment is repeated.
Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, can occur in patients treated with drugs classified as CD20-directed cytolytic antibodies, including rituximab products. Cases have been reported in patients who are hepatitis B surface antigen (HBsAg) positive and also in patients who are HBsAg negative but are hepatitis B core antibody (anti-HBc) positive. Reactivation also has occurred in patients who appear to have resolved hepatitis B infection (i.e., HBsAg negative, anti-HBc positive and hepatitis B surface antibody [anti-HBs] positive).

HBV reactivation is defined as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA levels or detection of HBsAg in a person who was previously HBsAg negative and anti-HBc positive. Reactivation of HBV replication is often followed by hepatitis, i.e., increase in transaminase levels. In severe cases increase in bilirubin levels, liver failure, and death can occur.

Screen all patients for HBV infection by measuring HBsAg and anti-HBc before initiating treatment with TRUXIMA. For patients who show evidence of prior hepatitis B infection (HBsAg positive [regardless of antibody status] or HBsAg negative but anti-HBc positive), consult with physicians with expertise in managing hepatitis B regarding monitoring and consideration for HBV antiviral therapy before and/or during TRUXIMA treatment.

Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following rituximab therapy. HBV reactivation has been reported up to 24 months following completion of TRUXIMA therapy.

In patients who develop reactivation of HBV while on TRUXIMA, immediately discontinue TRUXIMA and any concomitant chemotherapy, and institute appropriate treatment. Insufficient data exist regarding the safety of resuming TRUXIMA treatment in patients who develop HBV reactivation. Resumption of TRUXIMA treatment in patients whose HBV reactivation resolves should be discussed with physicians with expertise in managing HBV.
The present invention relates to regenerated silk having excellent mechanical properties. Particularly, provided are: a regenerated silk composition comprising silk fibroin having the specific distribution of the molecular weight, with excellent mechanical properties, the viscosity of a solution, and the like; a method for manufacturing the same; and a regenerated silk film comprising the same. The regenerated silk composition comprising silk fibroin has a silk molecular weight index greater than or equal to 11, which is represented by calculation formula 1. In calculation formula 1: the silk molecular weight index is equal to I_450 divided by I_150. The I_450 is the absorbance with respect to ultraviolet rays of 280 nm in the elution volume corresponding to 450 kDa in the molecular weight distribution of the silk fibroin. The I_150 is the absorbance with respect to ultraviolet rays of 280 nm in the elution volume corresponding to 150 kDa in the molecular weight distribution of the silk fibroin.
This study investigates the impact of social media-related microbreaks on the resource recovery of employees. Specifically, we examined whether or not the brief, hedonic use of social media through algorithmic videos could fully replenish resources, such as vigor and fatigue, that are depleted after performing clerical tasks. We also compared this form of recovery to other established microbreak activities. We used a pre-registered, mixed-method experimental design to collect data from 308 employees. A series of mixed-method ANOVA tests complemented by quadratic linear contrast terms and post-hoc analyses were performed to test hypotheses and address research questions. The findings indicate that although social media microbreaks offer a certain degree of resource replenishment, they do not provide full recovery, particularly regarding fatigue. Social media facilitate a reasonable psychological detachment but fall short in other recovery experiences. Notably, exposure to nature yielded more beneficial results. The study contributes novel insights to a field primarily focused on the negative impacts of excessive social media use and suggests that rational and brief usage can be advantageous for employee well-being.
With laughter, oxygen saturation in the brain and body increases. Laughter yoga basically includes breathing, meditation and different stretching movements. Benefits of laughter yoga; relaxes the muscles, reduces the level of stress hormones, ensures effective breathing, increases pain tolerance, strengthens mental functions, stimulates the circulatory and immune system, reduces anxiety and depression symptoms, improves quality of life and creates psychosocial well-being. Life satisfaction is the result obtained by comparing the expectations of the individual with what he has. Life satisfaction is affected by many factors such as daily stress, work life, social relations, and mental state. Life satisfaction is not related to certain areas, but to be happy in all areas of life.

Sleep is of great importance in fulfilling daily functions and in maintaining mental and physical health. sleep quality; It is the quantitative evaluation of sleep such as the time to fall asleep, the total time spent in sleep, the number of awakenings, and the duration of awakening.
Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
We designed a parallel, randomized, controlled, clinical trial. Eligible participants are adult, overweight and obese men and women, diagnosed with moderate-to-severe OSA \[apnea-hypopnea index (AHI)≥15 events/h\] through an attended overnight polysomnography. Participants, after written informed consent, were blindly randomized to a standard care group (SCG, n=37) and a Mediterranean diet group (MDG, n=37). Study groups were prescribed PAP. The SCG received oral healthy lifestyle advice and counseling on physical activity and sleep habits, while the MDG was additionally subjected to a 6-month behavioral intervention aiming at weight loss and increasing adherence to the Mediterranean diet. PAP adherence (hours of device use), BMI, daytime sleepiness, evaluated by Epworth Sleepiness Scale (ESS) and arterial blood pressure measurements were evaluated pre- and post-intervention.
There has been ongoing debate on the association between obesity and outcomes in acute myeloid leukemia (AML). Currently few studies have stratified outcomes by class I obesity, class II obesity, and class III obesity, and a more nuanced understanding is becoming increasingly important with the rising prevalence of obesity. We examined the association between body mass index (BMI) and outcomes in previously untreated AML in younger patients (age ≤60) enrolled in SWOG S1203 (n = 729). Class III obesity was associated with an increased rate of early death (p = 0.004) and worse overall survival (OS) in multivariate analysis (hazard ratio (HR) 2.48, 95% confidence interval (CI) 1.62-3.80 versus normal weight). Class III obesity was also associated with worse OS after allogeneic hematopoietic cell transplant (HR 2.37, 95% CI 1.24-4.54 versus normal weight). These findings highlight the unique risk of class III obesity in AML, and the importance of further investigation to better characterize this patient population.
Cisplatin is a chemotherapy drug that causes a plethora of DNA lesions and inhibits DNA transcription and replication, resulting in the induction of apoptosis in cancer cells. However, over time, patients develop resistance to cisplatin due to repeated treatment and thus the treatment efficacy is limited. Therefore, identifying an alternative therapeutic strategy combining cisplatin treatment along with targeting factors that drive cisplatin resistance is needed. CRISPR/Cas9 system-based genome-wide screening for the deubiquitinating enzyme (DUB) subfamily identified USP28 as a potential DUB that governs cisplatin resistance. USP28 regulates the protein level of microtubule-associated serine/threonine kinase 1 (MAST1), a common kinase whose expression is elevated in several cisplatin-resistant cancer cells. The expression level and protein turnover of MAST1 is a major factor driving cisplatin resistance in many cancer types. Here we report that the USP28 interacts and extends the half-life of MAST1 protein by its deubiquitinating activity. The expression pattern of USP28 and MAST1 showed a positive correlation across a panel of tested cancer cell lines and human clinical tissues. Additionally, CRISPR/Cas9-mediated gene knockout of USP28 in A549 and NCI-H1299 cells blocked MAST1-driven cisplatin resistance, resulting in suppressed cell proliferation, colony formation ability, migration and invasion in vitro. Finally, loss of USP28 destabilized MAST1 protein and attenuated tumor growth by sensitizing cells to cisplatin treatment in mouse xenograft model. We envision that targeting the USP28-MAST1 axis along with cisplatin treatment might be an alternative therapeutic strategy to overcome cisplatin resistance in cancer patients.
Patients receive pralatrexate IV over 3-5 minutes and oxaliplatin IV over 2 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Oxaliplatin will be discontinued after 12 courses.
In this study the investigators will investigate the mucus properties in individuals with idiopathic bronchiectasis and healthy individuals without a history of lung disease. In order to understand how mucus is abnormal in disease conditions, the investigators need to understand the mucus biochemical and biophysical properties in healthy individuals. In this study the investigators will prospectively recruit patients with bronchiectasis and healthy individuals from the community to provide airway sputum samples. In these samples the investigators will measure an array of mucus properties. This will help our understanding of the mucus-obstructive lung diseases and facilitate the development of appropriate and effective disease prevention strategies.

A key question is whether mucus is hyper-concentrated and has abnormal biophysical properties in individuals with mucus-obstructive lung disease. To answer this question, the investigators need to understand the properties of the mucus in individuals with idiopathic bronchiectasis and no history of lung disease. This study will allow us to collect airway mucus (sputum) from individuals with bronchiectasis and healthy individuals with no history of lung disease.
The mammalian brain's complete dependence on oxygen for ATP production makes it highly susceptible to hypoxia, at high altitudes or in clinical scenarios including anemia or pulmonary disease. Hypoxia plays a crucial role in the development of various brain disorders, such as Alzheimer's, Parkinson's, and other age-related neurodegenerative diseases. On the other hand, a decrease in environmental oxygen levels, such as prolonged stays at high elevations, may have beneficial impacts on the process of ageing and the likelihood of death. Additionally, the utilization of controlled hypoxia exposure could potentially serve as a therapeutic approach for age-related brain diseases. Recent findings indicate that the involvement of HIF-1α and the NLRP3 inflammasome is of significant importance in the development of Alzheimer's disease. HIF-1α serves as a pivotal controller of various cellular reactions to oxygen deprivation, exerting influence on a multitude of physiological mechanisms such as energy metabolism and inflammatory responses. The NLRP3 plays a crucial role in the innate immune system by coordinating the initiation of inflammatory reactions through the assembly of the inflammasome complex. This review examines the information pertaining to the contrasting effects of hypoxia on the brain, highlighting both its positive and deleterious effects and molecular pathways that are involved in mediating these different effects. This study explores potential strategies for therapeutic intervention that focus on restoring cellular balance and reducing neuroinflammation, which are critical aspects in addressing this severe neurodegenerative condition and addresses crucial inquiries that warrant further future investigations.